Orthocell Ltd reported positive early clinical results for its Remplir nerve repair technology in prostate cancer surgery, with 80% of patients regaining urinary continence and 75% showing erectile function recovery. The initial five-patient study supports plans for a larger clinical trial and expansion into the US market, potentially increasing Orthocell's addressable market to $2 billion. No additional regulatory approvals are needed for Remplir's use in prostatectomy in key markets, including the US. The company aims to validate these findings with a larger trial to promote broader adoption in nerve-sparing robotic prostate surgery.
Orthocell's Remplir nerve repair technology is highlighted alongside Pluang's health sector data. For readers following health stocks, here is Pluang's market snapshot as of Oct 13, 2026 04:51 WIB: Of 128 priced health-sector US stocks tradable on Pluang, 62 rose and 65 fell today. Moderna (MRNA) traded at USD 214.00 with a 1-day change of -4.89% and a typical hold time of 59 days, with Pluang order activity showing 45% sell and 55% buy. Adaptive Biotechnologies (ADPT) was priced at USD 25.21, down 4.83%, with a typical hold time of 36 days and 79% sell activity. Bruker Corporation (BRKR) traded at USD 56.03, down 4.78%, with a typical hold time of 4 days.
Kirby McInerney LLP is investigating Fervo Energy for potential securities law violations following the company's Q2 2026 earnings report and a critical research report. Fervo's shares fell sharply after it disclosed possible transmission issues at i...
Airbnb reports a surge in fall travel, with 60% of Americans planning weekend getaways, especially families with infants. Gen Z is driving a trend called lore-tripping, seeking unique local stories, while sports fans engage in groundhopping to iconic...
In Q3 2026, TRON DAO reported a milestone of $2.21 trillion in stablecoin settlements, with the network surpassing $30 trillion in cumulative transaction volume. The active user base grew by nearly 10%, and stablecoin supply increased to $93.88 billi...
Bureau Veritas disclosed its share buyback transactions conducted between October 5 and October 9, 2026. This activity reflects the company's ongoing efforts to manage its capital structure and potentially enhance shareholder value. Investors should ...
Bureau Veritas disclosed its treasury shares transactions conducted between October 5 and October 9, 2026. This update is part of the company's regular reporting obligations to inform investors about changes in its treasury shares holdings. Such disc...
